Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 7, 2019

Study Completion Date

May 7, 2019

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

Pomalidomide

4 mg PO x 21 days

DRUG

Cyclophosphamide

low dose cyclophosphamide 50 mg PO BID x 21 days

DRUG

Dexamethasone

dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Ajai Chari

OTHER